Dr. Jiali Luo brings extensive experience in management and operations of biopharmaceuticals in China and overseas and possesses a wide ranged background in development, manufacturing, quality systems and commercial supply.
Chicago, IL., May. 20, 2021 – Meitheal Pharmaceuticals, Inc., a fully integrated generic injectables company based in Chicago, Illinois today announced that Dr. Jiali Luo has joined its parent company, Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (NKF), as General Manager. Dr. Luo will be a key member of the executive team which sets the overall strategic direction of NKF’s biopharmaceutical business. In addition, he will guide development, manufacturing and commercial supply for the Company’s biopharmaceutical products and support the shared services initiatives of NKF’s subsidiaries, including Meitheal.
“We are very excited to have Dr. Luo join our leadership team as we continue to progress our biopharmaceuticals pipeline to address unmet needs in global health. Dr. Luo’s experience in management and operation of biopharmaceutical products both in China and globally will be valuable during this period of growth for the company,” said Eric Tang, CEO of NKF.
Dr. Luo graduated with a Master’s and PhD degree in Biochemistry and Protein Science from Karolinska Institute at Stockholm, Sweden in 1997 and also obtained his MBA degree from Fogelman College of Business and Economy at the University of Memphis, USA.
Dr. Luo’s past positions include Vice President of Boerheringer Ingelheim China and General Manager of Boerheringer Ingelheim Biopharmaceuticals (China) Ltd., Co. leading its biopharmaceutical business and operations from 2014 through 2021. Prior to that, Dr. Luo held several management positions at Hisun Pharmaceutical Co. from 2002 through 2013 as Director of R&D, Head of Biopharmaceuticals, Vice President of Business Development and Chief Officer of Global Commercialization.
"I am honored to be joining NKF and look forward to working with the outstanding leadership team here in progressing the Company's pipeline as well as supporting other initiatives with NKF’s subsidiaries, including Meitheal, with the goal of addressing unmet needs for patients," said Dr. Luo. "
ABOUT MEITHEAL PHARMACEUTICALS
Since 2017, Meitheal Pharmaceuticals has bridged critical gaps in the US healthcare market by supplying high quality, affordable generic injectables. Our diversified product range — from antibiotics, anticoagulants, and muscle relaxants to drugs used in chemotherapy — represents practical solutions for countless patients around the country, as well as Meitheal’s commitment to their care. Based in Chicago, Illinois, our aim each day is producing quality and ensuring affordability, using the traditional Irish guiding principle we are named for — Meitheal (Mee·hall): working together toward a common goal, for the greater good.
Learn more about who we are and what we do at www.meithealpharma.com.
ABOUT NANJING KING-FRIEND BIOPHARMACEUTICAL COMPANY (NKF)
NKF is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredients (API) and Finished Dosage Form (FDF). Established in 1986 as one of world leading manufacturers of heparin related APIs, NKF has grown into a fully integrated API and FDF manufacturer in multiple therapeutic areas including critical care and oncology. With three US FDA approved manufacturing sites in China and more than 500 employees, including more than 100 dedicated research and development experts, NKF strives to meet patient needs globally with market presence at US, China, EU and South America. The Company is publicly listed on Shanghai Stock Exchange with a market capitalization over $3B.
Meitheal Pharmaceuticals, Inc.
Thomas Shea, CEO
224 443 4522